Login to MyKarger

New to MyKarger? Click here to sign up.



Login with Facebook

Forgot your password?

Authors, Editors, Reviewers

For Manuscript Submission, Check or Review Login please go to Submission Websites List.

Submission Websites List

Institutional Login
(Shibboleth or Open Athens)

For the academic login, please select your country in the dropdown list. You will be redirected to verify your credentials.

Gynecologic Cytopathology

Editor's Choice - Free Access

Human Papillomavirus Genotype Distribution in Cytologically Screened Women from Northwest Germany

de Jonge M.a · Busecke G.b · Heinecke A.c · Bettendorf O.a

Author affiliations

aInstitute of Pathology and Cytology Schüttorf/Leer, Schüttorf, bMedical Office of General Medicine, Weener, and cDepartment of Medical Informatics and Biomathematics, University of Münster, Münster, Germany

Corresponding Author

Correspondence to: PD Dr. med. Olaf Bettendorf

Institute of Pathology and Cytology Schüttorf/Leer

Technikerstrasse 14

DE-48465 Schüttorf (Germany)

E-Mail O_Bettendorf@web.de

Related Articles for ""

Acta Cytologica 2013;57:591-598

Abstract

Introduction: In this study, we evaluate the distribution of 24 human papillomavirus (HPV) genotypes in a cohort of 3,381 cytologically screened women from a rural area of northwest Germany, in correlation to cytological diagnoses and histological outcomes. Materials and Methods: We present a retrospective study in which the HPV-genotyping results of women who attended the German cervical screening program were correlated to cytological diagnosis and histological outcome. Results: HPV genotyping showed marked differences among cervical lesions. Although HPV-51 was common in all cervical lesions, it was rarely detected as single-type HPV infection in high-grade cervical intraepithelial neoplasia (CIN)3 (2/118 cases). HPV-16 and 18 were more common in CIN3 (57.6%) than in CIN2 (21.8%), but they were absent in 42.4% of all CIN3 lesions in our cohort. Discussion: Our data show that HPV-16, HPV-31, HPV-51, HPV-53 and HPV-42 are the most prevalent HPV types in the different cervical lesions in this region of northwest Germany. HPV genotyping has been shown to be a powerful tool to triage atypical squamous cells of undetermined significance lesions. Considering the observed heterogeneity of HPV types in CIN2, it could also be useful to triage CIN2+ lesions. Our results underline the usefulness of a morphologically controlled screening program with HPV genotyping as a powerful additional tool.

© 2013 S. Karger AG, Basel


Introduction

Persistent human papillomavirus (HPV) infection is the main cause for the development of cervical cancer. About 40 different HPV types can infect the anogenital tract, of which 18 HPV types (16, 18, 31, 33, 35, 39, 45, 51, 52, 53, 56, 58, 59, 66, 68, 70, 73 and 82) are defined (as probably) high-risk for the development of high-grade cervical intraepithelial neoplasia (CIN)2+ and cervical cancer [1,2].

Some high-risk HPV (hrHPV) types are more carcinogenic than others [3]. HPV-16 is the most prevalent type found in 40-70% of cervical cancer cases worldwide, followed by HPV-18 which has an overall prevalence of 15% [4]. HPV genotyping has been shown to have a greater sensitivity with a slightly lower specificity for the detection of CIN2+ lesions compared to cytology [5]. This increased sensitivity can lead to earlier detection and better protection against cervical lesions, although, due to lower specificity, more women need follow-up examinations because of clinically irrelevant positive results. This is one of the reasons why HPV-DNA testing has not yet been used for primary cervical screening. In the Netherlands, however, hrHPV screening is now being considered as a primary screening method for cervical cancer, with cytology used for triage in case of positive hrHPV results [6,7,8]. Molecular methods for HPV detection have become a powerful tool for the management of suspicious cervical cytology over the last decades [9], as the presence of specific hrHPV types can be used as an indicator of the risk for developing CIN2+ lesions. The distribution of HPV types varies between countries and little is known about the HPV genotype distribution in correlation to cytological diagnosis and histological outcome in this region of Germany [10,11,12,13,14,15].

The aim of this study was to investigate the distribution of 24 HPV genotypes in a cytologically screened population coming from a rural area of northwest Germany in correlation to cytological diagnosis and histological outcome, and to evaluate its impact on primary HPV screening and vaccination.

Materials and Methods

Study Population

The HPV-genotyping results of 3,714 women (mean age 38 years) processed between the years 2008 and 2010 were collected and correlated to cytological and histological examinations (4,120 results). Patients came from the rural regions of northwest Germany (Nordrhein-Westfalen, Niedersachsen, Schleswig-Holstein, Bremen and Hamburg) and participated in the German annual cervical screening program for women ≥20 years of age [16]. HPV genotyping was performed in the case of normal cytology only if requested by the patient, or else on clinical indication in the case of abnormal cytology, i.e. atypical squamous cells of undetermined significance (ASC-US), atypical squamous cells cannot exclude HSIL (ASC-H), low-grade squamous intraepithelial lesion (LSIL), encompassing mild dysplasia/CIN1, high-grade squamous intraepithelial lesion (HSIL), encompassing moderate and severe dysplasia/CIN2 and CIN3 or atypical glandular cells of undetermined significance (AGUS). No samples were collected solely for this study. Exclusion criteria were no corresponding cytology, a history of total hysterectomy and an age of <30 years together with an unknown vaccination status.

Currently, there are two approved vaccines for the prevention of cervical cancer, Gardasil®, a quadrivalent vaccine directed against HPV-16, HPV-18, HPV-6 and HPV-11 and Cervarix®, a bivalent vaccine directed against HPV-16 and HPV-18 [17,18].

Strict adherence to the manufacturer's instructions for the HPV vaccination is a prerequisite for a correct calculation of the immunological response. This requirement was not fulfilled in most of the patients in our study, therefore all vaccinated patients were excluded.

All Papanicolaou (PAP) smears, biopsies and HPV-genotyping tests were processed at the Institute of Pathology/Cytology Schüttorf/Leer, an ISO (International Organization for Standardization) 9001:2008 certified laboratory.

Cytological samples were classified according to the Bethesda 2001 system [19]. Cytological samples were taken in gynecology practices using the Rovers® Cervex-Brush®. Both conventional smears and liquid-based cytology (SurePath®) were used.

Histological lesions were classified according the WHO-classification (CIN I-III).

Immunohistochemistry was used to detect overexpression of the cell-cycle protein p16INK4a, a cyclin-dependent kinase inhibitor. Cervical neoplasia expresses high levels of p16INK4a in contrast to other cervical epithelia. This overexpression is linked to oncogenic transformation mediated by persistent hrHPV infection and it has been shown to significantly improve the accuracy of grading CIN lesions [20,21].

In the case of a PAP-IV (HSIL) lesion or a recurrent PAP-IIID lesion with moderate dysplasia (HSIL) for more than 1 year, a colposcopy together with histological confirmation was advised.

The PapilloCheck® assay, a commercially available HPV genotyping assay which has been reported as a compatible test to established PCR assays [22,23] was used for the qualitative detection and identification of 18 hrHPV types (16, 18, 31, 33, 35, 39, 45, 51, 52, 53, 56, 58, 59, 66, 68, 70, 73 and 82) and 6 low-risk HPV types (6, 11, 40, 42, 43 and 44/55). The test was performed according to the manufacturer's instructions. A negative control (sample without DNA) was added to each chip to exclude false-positive results, which can occur by contamination during the process. Cytological samples that were correlated to HPV-genotyping results had to be taken within 1 month before or after the HPV-genotyping test was performed. In case of liquid-based cytology, DNA from cervical smears was isolated from residual SurePath® samples. When a conventional smear was made, an additional smear using the HC cervical sampler® (Digene) was taken for HPV detection. All histological samples were taken within 3 months after cytological diagnosis; we did not separately perform HPV genotyping on histological samples consecutively, HPV genotyping results from the corresponding cytological samples were matched to the CIN lesions.

Statistical analysis software SPSS 17.0 (SPSS Inc., Chicago, Ill., USA) and SAS 9.3 (SAS Institute, Inc., Cary, N.C., USA) were used. The Pearson χ2 test calculated p values, with p < 0.05 being considered statistically significant.

Results

In total, 3,381 of 3,714 women fulfilled the inclusion criteria. Population characteristics of our cohort are summarized in table 1. AGUS was diagnosed in 33 of 3,381 specimens; HPV distribution in these cervical lesions will not be discussed in this article.

Table 1

Population characteristics

http://www.karger.com/WebMaterial/ShowPic/186333

The HPV distribution according to cytological diagnosis is shown in table 2. Increasing severity of cytological lesions was associated with higher prevalence rates of HPV infection (but not significant for LSIL vs. HSIL, p = 0.0654) and especially with higher prevalence rates of hrHPV infection (p < 0.001).

Table 2

HPV type distribution according to cytological diagnosis

http://www.karger.com/WebMaterial/ShowPic/186332

Low-risk HPV was significantly more common (p < 0.0001) in LSIL (32.9%) compared to normal cytology (8.3%), ASC-US (15.0%), ASC-H (11.5%) and HSIL (19.4%).

The distribution of HPV type varied among cytological and histological lesions. The most common HPV types in cytological lesions are in recorded in bold type in table 2. The most prevalent HPV types were: HPV-51 (6.8%) in normal cytology, HPV-42 (9.9%) in ASC-US, HPV-16 (28.7%) in ASC-H, HPV-42 (23.8%) in LSIL and HPV-16 (34.4%) in HSIL.

HPV-6 (varying from 1.5 to 2.9%) and HPV-11 (varying from 0.0 to 0.7%) were uncommon in our cohort.

In histological lesions, the most prevalent HPV types were: both HPV-16 and HPV-42 (25.8%) for CIN1, HPV-51 (25.5%) for CIN2 and HPV-16 (52.5%) for CIN3. The distribution of HPV types in both CIN2 and CIN3 is shown in figure 1. With regard to CIN3, HPV-16, HPV-18 and HPV-31 were more common as single-type than multiple-type infections compared to the other HPV types. Low-risk HPV types and HPV-35, HPV-59 and HPV-68 were not found as single-type HPV infections in CIN2+ lesions. HPV-66, HPV-70 and HPV-73 were only detected as single-type HPV infections in CIN2, but not in CIN3.

Fig. 1

Type-specific HPV prevalence in CIN2 (a) and CIN3 (b) lesions.

http://www.karger.com/WebMaterial/ShowPic/186331

The prevalence of HPV-16 and HPV-18 in cytological and histological lesions is shown in figure 2. Infections with HPV-16 and 18 were more common in HSIL (39.7%) and in ASC-H (32.2%) compared to in ASC-US (10.0%) and in LSIL (21.1%) (p < 0.0001). Regarding histology, HPV-16 and HPV-18 were significantly more common in CIN3 (57.6%) than in CIN2 (21.8%) (p < 0.0001). In contrast, hrHPV types other than HPV-16 and HPV-18 were significantly more common (p < 0.0001) in CIN2 (76.4%) than in CIN3 (39.8%).

Fig. 2

Comparison between the prevalence of HPV-16 and HPV-18 compared to other high-risk types. Every lesion positive for HPV-16 and/or HPV-18 was counted to the category HPV-16/18, irrespective to other hrHPV types. Every lesion positive for other high-risk types (31, 33, 35, 39, 45, 51, 52, 53, 56, 58, 59, 66, 68, 70, 73 and 82) without the presence of HPV-16 or HPV-18 was counted to other high-risk types. The error bars indicate the 95% confidence intervals.

http://www.karger.com/WebMaterial/ShowPic/186330

Discussion

The overall HPV prevalence in women with normal cytology was 29.8%. This rate is high compared to the study of Klug et al. [12] and the WHO/ICO HPV Information Centre [24] which reported HPV prevalence rates of 4.4 and 6.9%, respectively, in women with normal cytology in Germany [12,24], or compared to the meta-analysis of de Sanjosé et al. [10], in which a worldwide overall HPV prevalence of 10,8% was found in women with normal cytology, with a corresponding estimate by region of 8.1% for Europe. The study of Kovács et al. [25] reported an overall HPV prevalence rate of 24.2% among 5,934 women (2,217 specimens with normal cytology) who only received one HPV test; however, since this study did not separately analyze the cytological diagnosis, the results are difficult to compare. A possible explanation for the high HPV prevalence found among women with normal cytology in our study population is the fact that they underwent primary cytological screening and were only tested for HPV if the patient or clinician wished, which might have introduced a selection bias. Furthermore, we did not exclude women with previous abnormal PAP smears. Other possible explanations for the observed differences among the studies could be the use of different HPV genotyping assays with different sensitivities for HPV detection [26,27]. In the review of Snijders et al. [26], analytical performances of the Hybrid capture II method and the consensus PCR assays PGMY-PCR, GP5+-6+-PCR and SPF10 were discussed. It was seen that the estimated HPV prevalence rates, particularly in women with normal cytology, varied dramatically depending on the method used. They also discussed a study comparing the SPF1/2 (a former version of SPF10) with the GP5+/6+-PCR assay, in which significantly more HPV-DNA was detected in cervical scrapes from women with normal cytology when using the SPF1/2, whereas HPV prevalence rates found in abnormal smears did not significantly differ between the assays. These differences might be explained by a wide range in HPV viral load, particular in women with normal cytology, and the estimated HPV prevalence rate in this group may be proportional to the analytical sensitivity of the genotyping test used [26].

Recent studies reported significant variation in hrHPV prevalence rates for women diagnosed with ASC-H (33.3-85.6%), ASC-H is a relatively uncommon diagnosis and although cytomorphologic criteria have been described, there is still a great interobserver and even intraobserver variability, resulting in limited reproducibility. Considering that the highest HPV-positive rates have been reported in multicenter trials using consensus panel diagnoses compared to most local practice settings which reported lower HPV-positive rates using the interpretation of a single pathologist, interinstitutional variation in PAP test diagnosis could also partly explain the high HPV prevalence rate found; however, interpretation of normal cytology is generally a less interpretive challenge [28,29,30,31].

Other explanations could be the different demographic and geographic characteristics of the cohorts and the different screening models in each country. We also included women <30 years of age; HPV prevalence is higher in this age category, so this could also partly explain the finding of an unusually high prevalence [32].

In contrast to the high HPV prevalence rate in normal cytology, hrHPV prevalence rates in abnormal cytological lesions were mostly consistent with other national and international studies [11,13,33], although discrepancies were observed with the study of Evans et al. [14 ]who reported lower hrHPV prevalence rates for LSIL (55.0 vs. 78.9% in our cohort) and higher hrHPV prevalence rates for ASC-H (80.0 vs. 62.1% in our cohort).

The fact that ASC-US cytology had a considerably lower hrHPV positivity rate (43.2%) compared to other abnormal cytological lesions (p < 0.0001) makes women with ASC-US good candidates for triage by HPV genotyping, which is also advised in the European Guidelines for Quality Assurance in Cervical Cancer Screening [9].

We observed a strong variability in the most prevalent HPV types detected in the different cytological and histological lesions, which was less pronounced in high-grade lesions (ASC-H, HSIL and CIN2+), especially when only single-type HPV infections were considered. The most prevalent types considering single-type HPV infections in CIN3 were HPV-16, HPV-31 and HPV-18. These types together with HPV-33 and HPV-45 are the most commonly detected in cervical cancer in Europe [4]. In Germany, the 5 most prevalent HPV types detected in cervical cancer are HPV-16 (58%), HPV-18 (18.8%), HPV-52 (5.6%), HPV-68 (5.6%) and HPV-31 (2.9%) [24]. Except for HPV-68 which was not detected as single-type infection in CIN2+ lesions, these HPV types were the most prevalent when considering single-type HPV infection in CIN3 in our study population (fig. 1). This indicates that although there are marked differences in HPV prevalence within low-grade lesions (ASC-US, LSIL and CIN1) between regions and countries [10,11,13,14,15,24], the HPV types most often causing cervical cancer probably remain the same. It is important to take this into account, since both the cost-effectiveness and the specificity for the detection of CIN2+ lesions will decrease when infections that only rarely progress to cancer undergo screening [15]. In our population, HPV-51 was one of the most commonly detected hrHPV genotypes for every lesion. However, it was rarely detected as a single infection in CIN3 (n = 2/58). There are no studies that reported the Papillocheck® to have an unusually high sensitivity for the detection of HPV-51. Furthermore, this was not the first study that found high prevalence rates for HPV-51 in Germany [12,34,35]. Therefore, we assume that HPV-51 is a common genotype in our cohort which is not biased by test characteristics.

Screening for HPV-51 would not be effective in our cohort, as it would yield many irrelevant positive results since an infection with HPV-51 alone rarely causes cervical cancer. The issue for which oncogenic screening for HPV type should be useful becomes difficult when taking into consideration that the most prevalent HPV types are dependent on geography and age [10,12,32,34,36]. This also underlines the usefulness of a morphologically controlled screening program with HPV genotyping as a powerful additional tool or opting to triage HPV-positive screening results in the future.

Another very common HPV type in our cohort was HPV-42. The Papillocheck® has proven to be more sensitive than other assays in the detection of HPV-42 [34], which might be an explanation for the high prevalence of HPV-42 in our cohort. This demonstrates the importance of standardizing HPV genotyping assays.

The prevalence of HPV-16 and HPV-18 increased with more severe cytological and histological lesions. These types were detected in 57.6% of the CIN3 lesions, which corresponds to other studies [12,14,37,38]. We observed a marked difference between CIN2 and CIN3 regarding the contribution of HPV-16 and HPV-18, compared to other high-risk types. HPV-16 and 18 were significantly more common in CIN3 than in CIN2, whereas other high-risk types were more common in CIN2 than in CIN3. Although it is known that CIN2 lesions are more heterogeneous and more likely to regress [39], many studies combine these two cervical lesions when determining HPV distribution because the European Guidelines for Quality Assurance in Cervical Cancer Screening advise treating both CIN2 and CIN3 by excision of the transformation zone without delay in the presence of high-grade intraepithelial neoplasia (CIN2+) or suspicion of early stromal invasion or microinvasion [9,12,14].

Our data, however, show that HPV genotyping could be useful for triage of women with CIN2 lesions to assess which women are harboring the HPV genotypes that are commonly detected in cervical cancer. Doing so could prevent overtreatment, especially when considering that only 5% of the CIN2 lesions indeed progress to invasive cancer [39]. A possible explanation for the large differences between CIN2 and CIN3 in the distribution of HPV type, as observed in our study, could be the additive use of immunohistochemistry to detect overexpression of the cell cycle protein p16INK4a for histological grading of CIN lesions. This immunohistochemical method has been shown to improve the accuracy of grading CIN lesions significantly [20,21].

HPV-31 was three times as common as HPV-18 in CIN3. Although it is demonstrated that the current vaccine gives a certain cross-protection against HPV-31 [40], a direct vaccination against HPV-31 would have been useful in our cohort.

A vaccine directed against HPV-51 would have prevented many abnormal cytological lesions but only a few high-grade histological lesions. It would not have prevented many invasive cervical cancers either, as only 1% (28/2,058) of all cervical cancer in Europe is caused by HPV-51 [4]. Therefore, a vaccine against HPV-51 would have reduced the diagnostic follow-up of women with abnormal cytology, but it would not have prevented many high-grade histological lesions and consequent surgical treatments. A vaccine against HPV-42 would also have been effective in the prevention of low-grade cytological and histological lesions (ASC-US, LSIL and CIN1), especially when considering that almost all HPV-42 infections show the histological characteristics of genital condylomata or flat papillomas [41].

In particular, vaccination would have prevented high-grade lesions as these most often contained HPV-16 and HPV-18. Because other hrHPV types were more common in low-grade lesions, many women would probably still have developed abnormal cytology.

Acknowledgements

The authors would like to thank Nicole Niemann, Thea van Wüllen and Jan Ebbecke for perfect technical work and Sandra Minns, as native speaker, for carefully reading the manuscript.


References

  1. Bosch FX, Lorincz A, Muñoz N, Meijer CJ, Shah KV: The causal relation between human papillomavirus and cervical cancer. J Clin Pathol 2002;55:244-265.
    External Resources
  2. Walboomers JM, Jacobs MV, Manos MM, Bosch FX, Kummer JA, Shah KV, Snijders PJ, Peto J, Meijer CJ, Muñoz N: Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol 1999;189:12-19.
  3. Schiffman M, Herrero R, Desalle R, Hildesheim A, Wacholder S, Rodriguez AC, Bratti MC, Sherman ME, Morales J, Guillen D, Alfaro M, Hutchinson M, Wright TC, Solomon D, Chen Z, Schussler J, Castle PE, Burk RD: The carcinogenicity of human papillomavirus types reflects viral evolution. Virology 2005;337:76-84.
  4. de Sanjose S, Quint WG, Alemany L: Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide study. Lancet Oncol 2010;11:1048-1056.
  5. Cuzick J, Clavel C, Petry KU, Meijer CJ, Hoyer H, Ratnam S, Szarewski A, Birembaut P, Kulasingam S, Sasieni P, Iftner T: Overview of the European and North American studies on HPV testing in primary cervical cancer screening. Int J Cancer 2006;119:1095-1101.
  6. de Kok IM, van Rosmalen J, Dillner J, Arbyn M, Sasieni P, Iftner T, van Ballegoojen M: Primary screening for human papillomavirus compared with cytology screening for cervical cancer in European settings: cost effectiveness analysis based on a Dutch microsimulation model. BMJ 2012;344:e670.
  7. Kijkaart DC, Berkhof J, van Kemenade FJ, Coupe VM, Rozendaal, Heideman DA, Verheijen RH, Bulk S, Verweig W, Snijders PJ, Meijer CJ: HPV DNA testing in population-based cervical screening (VUSA-Screen study): results and implications. Br J Cancer 2012;106:975-981.
  8. Farnsworth A: Screening for the prevention of cervical cancer in the era of human papillomavirus vaccination: an Australian perspective. Acta Cytol 2011;55:307-312.
  9. Arbyn M, Anttila A, Jordan J, Schenck U, Ronco G, Segnan N, Wiener H, Herbert A, Daniel J, von Karsa L: European Commission. European Guidelines for Quality Assurance in Cervical Cancer Screening. Second edition - summary document. Ann Oncol 2010;21:448-455.
  10. de Sanjosé S, Diaz M, Castellsagué X, Clifford G, Bruni L, Muñoz N, Bosch FX: Worldwide prevalence and genotype distribution of cervical human papillomavirus DNA in women with normal cytology, a meta-analysis. Lancet Infect Dis 2007;7:453-459.
  11. Garcia-García JA, Pérez-Vallés A, Martorell M, Gómez B, Gómez-Cabrero D, Soler F, Calabuig C: Distribution of human papillomavirus types in women from Valencia, Spain, with abnormal cytology. Acta Cytol 2010;54:159-164.
  12. Klug SJ, Hukelmann M, Hollwitz B, Düzenli N, Schopp B, Petry KU, Iftner T: Prevalence of human papillomavirus types in women screened by cytology in Germany. J Med Virol 2007;79:616-625.
  13. Agarossi A, Ferrazzi E, Parazzini F, Perno CF, Ghisoni L: Prevalence and type distribution of high-risk human papillomavirus infection in women undergoing voluntary cervical cancer screening in Italy. J Med Virol 2009;81:529-535.
  14. Evans MF, Adamson CS, Papillo JL, St John TL, Leiman G, Cooper K: Distribution of human papillomavirus types in ThinPrep Papanicolaou tests classified according to the Bethesda 2001 terminology and correlations with patient age and biopsy outcomes. Cancer 2006;106:1054-1064.
  15. Forslund O, Antonsson A, Edlund K, van den Brule AJ, Hansson BG, Meijer CJ, Ryd W, Rylander E, Strand A, Wadell G, Dillner J, Johansson B: Population-based type-specific prevalence of high-risk human papillomavirus infection in middle-aged Swedish women. J Med Virol 2002;66:535-541.
  16. Schenck U, von Karsa L: Cervical cancer screening in Germany. Eur J Cancer 2000;36:2221-2226.
  17. Stanley M, Lowy DR, Frazer I: Chapter 12, Prophylactic HPV vaccines, underlying mechanisms. Vaccine 2006;24:106-113.
  18. Einstein MH, Baron M, Levin MJ, Chatterjee A, Fox B, Scholar S, Rosen J, Chakhtoura N, Meric D, Dessy FJ, Datta SK, Descamps D, Dubin G, HPV-010 Study Group: Comparative immunogenicity and safety of human papillomavirus (HPV)-16/18 vaccine and HPV-6/11/16/18 vaccine: follow-up from months 12-24 in a phase III randomized study of healthy women aged 18-45 years. Hum Vaccin 2011;7:1343-1358.
  19. Solomon D, Davey D, Kurman R, Moriarty A, O'Connor D, Prey M, Raab S, Sherman M, Wilbur D, Wright T, Young N; Forum Group Members, Bethesda 2001 Workshop: The 2001 Bethesda System, terminology for reporting results of cervical cytology. JAMA 2002;287:2114-2119.
  20. Dijkstra MG, Heideman DA, de Roy SC, Rozendaal L, Berkhof J, van Krimpen K, van Groningen K, Snijders PJ, Meijer CJ, van Kemenade FJ: p16(INK4a) immunostaining as an alternative to histology review for reliable grading of cervical intraepithelial lesions. J Clin Pathol 2010;63:972-977.
  21. Gustinucci D, Passamonti B, Cesarini E, Butera D, Palmieri EA, Bulletti S, Carlani A, Staiano M, D'Amico MR, D'Angelo V, Di Dato E, Martinelli N, Malaspina M, Spita N, Tintori B, Fulciniti F: Role of p16(INK4a) cytology testing as an adjunct to enhance the diagnostic specificity and accuracy in human papillomavirus-positive women within an organized cervical cancer screening program. Acta Cytol 2012;56:506-514.
  22. Hesselink AT, Heideman DA, Berkhof J, Topal F, Pol RP, Meijer CJ, Snijders PJ: Comparison of the clinical performance of PapilloCheck human papillomavirus detection with that of the GP5+/6+-PCR-enzyme immunoassay in population-based cervical screening. J Clin Microbiol 2010;48:797-801.
  23. Schopp B, Holz B, Zago M, Stubenrauch F, Petry KU, Kjaer SK, Iftner T: Evaluation of the performance of the novel PapilloCheck HPV genotyping test by comparison with two other genotyping systems and the HC2 test. J Med Virol 2010;82:605-615.
  24. WHO/ICO Information Centre on HPV and Cervical Cancer (HPV Information Centre): Human papillomavirus and related cancers in Germany. Summary report 2010. www.who.int/hpvcentre (accessed April 12, 2013).
  25. Kovács K, Varnai AD, Bollmann M, Bankfalvi A, Szendy M, Speich N, Schmitt C, Pajor L, Bollmann R: Prevalence and genotype distribution of multiple human papillomavirus infection in the uterine cervix: a 7.5-year longitudinal study in a routine cytology-based screening population in West Germany. J Med Virol 2008;80:1814-1823.
  26. Snijders PJ, van den Brule AJ, Meijer CJ: The clinical relevance of human papillomavirus testing, relationship between analytical and clinical sensitivity. J Pathol 2003;201:1-6.
  27. Klug SJ, Molijn A, Schopp B, Holz B, Iftner A, Quint W,JF Snijders P, Petry KU, Krüger Kjaer S, Munk C, Iftner T: Comparison of the performance of different HPV genotyping methods for detecting genital HPV types. J Med Virol 2008;80:1264-1274.
  28. Bandyopadhyay S, Austin RM, Dabbs D, Zhao C: Adjunctive human papillomavirus DNA testing is a useful option in some clinical settings for disease risk assessment and triage of females with ASC-H Papanicolaou test results. Arch Pathol Lab Med 2008;132:1874-1881.
    External Resources
  29. Davey DD, Greenspan DL, Kurtycz DF, Husain M, Austin RM: Atypical squamous cells, cannot exclude high-grade squamous intraepithelial lesion: review of ancillary testing modalities and implications for follow-up. J Low Genit Tract Dis 2010;14:206-214.
  30. Washiya K, Takamizu R, Kumagai Y, Himeji Y, Kobayashi T, Iwai M, Watanabe J: Worldwide web-based cytological analysis of atypical squamous cells cannot exclude high-grade intraepithelial lesions. Acta Cytol 2012;56:47-54.
  31. Stoler MH, Schiffman M, Atypical Squamous Cells of Undetermined Significance-Low-grade Squamous Intraepithelial Lesion Triage Study (ALTS) Group: Interobserver reproducibility of cervical cytologic and histologic interpretations, realistic estimates from the ASCUS-LSIL Triage Study. JAMA 2001;285:1500-1505.
  32. Smith JS, Melendy A, Rana RK, Pimenta JM: Age-specific prevalence of infection with human papillomavirus in females, a global review. J Adolesc Health 2008;43:5-25.
  33. The Atypical Squamous Cells of Undetermined Significance/Low-Grade Squamous Intraepithelial Lesions Triage Study (ALTS) Group: Human papillomavirus testing for triage of women with cytologic evidence of low-grade squamous intraepithelial lesions, baseline data from a randomized trial. J Natl Cancer Inst 2000;92:397-402.
  34. Iftner T, Eberle S, Iftner A, Holz B, Banik N, Quint W, Straube AN: Prevalence of low-risk and high-risk types of human papillomavirus and other risk factors for HPV infection in Germany within different age groups in women up to 30 years of age, an epidemiological observational study. J Med Virol 2010;82:1928-1939.
  35. Bollmann R, Bankfalvi A, Griefingholt H, Trosic A, Speich N, Schmitt C, Bollmann M: Validity of combined cytology and human papillomavirus (HPV) genotyping with adjuvant DNA-cytometry in routine cervical screening, results from 31,031 women from the Bonn region in West Germany. Oncol Rep 2005;13:915-922.
    External Resources
  36. Clifford GM, Rana RK, Franceschi S, Smith JS, Gough G, Pimenta JM: Human papillomavirus genotype distribution in low-grade cervical lesions, comparison by geographic region and with cervical cancer. Cancer Epidemiol Biomarkers Prev 2005;14:1157-1164.
  37. Smith JS, Lindsay L, Hoots B, Keys J, Franceschi S, Winer R, Clifford GM: Human papillomavirus type distribution in invasive cervical cancer and high-grade cervical lesions, a meta-analysis update. Int J Cancer 2007;121:621-632.
  38. Bosch FX, Burchell AN, Schiffman M, Giuliano AR, de Sanjose S, Bruni L, Tortolero-Luna G, Kjaer SK, Muñoz N: Epidemiology and natural history of human papillomavirus infections and type-specific implications in cervical neoplasia. Vaccine 2008;26(suppl 10):K1-K16.
  39. Ostör AG: Natural history of cervical intraepithelial neoplasia, a critical review. Int J Gynecol Pathol 1993;12:186-192.
  40. Brown DR, Kjaer SK, Sigurdsson K, Iversen OE, Hernandez-Avila M, Wheeler CM, Perez G, Koutsky LA, Tay EH, Garcia P, Ault KA, Garland SM, Leodolter S, Olsson SE, Tang GW, Ferris DG, Paavonen J, Steben M, Bosch FX, Dillner J, Joura EA, Kurman RJ, Majewski S, Muñoz N, Myers ER, Villa LL, Taddeo FJ, Roberts C, Tadesse A, Bryan J, Lupinacci LC, Giacoletti KE, Sings HL, James M, Hesley TM, Barr E: The impact of quadrivalent human papillomavirus (HPV; types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in generally HPV-naive women aged 16-26 years. J Infect Dis 2009;199:926-935.
  41. Philipp W, Honoré N, Sapp M, Cole ST, Streeck RE: Human papillomavirus type 42, new sequences, conserved genome organization. Virology 1992;186:331-334.

Author Contacts

Correspondence to: PD Dr. med. Olaf Bettendorf

Institute of Pathology and Cytology Schüttorf/Leer

Technikerstrasse 14

DE-48465 Schüttorf (Germany)

E-Mail O_Bettendorf@web.de


Article / Publication Details

First-Page Preview
Abstract of Gynecologic Cytopathology

Received: March 04, 2013
Accepted: August 18, 2013
Published online: October 04, 2013
Issue release date: November – December

Number of Print Pages: 8
Number of Figures: 2
Number of Tables: 2

ISSN: 0001-5547 (Print)
eISSN: 1938-2650 (Online)

For additional information: https://www.karger.com/ACY


Copyright / Drug Dosage / Disclaimer

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

References

  1. Bosch FX, Lorincz A, Muñoz N, Meijer CJ, Shah KV: The causal relation between human papillomavirus and cervical cancer. J Clin Pathol 2002;55:244-265.
    External Resources
  2. Walboomers JM, Jacobs MV, Manos MM, Bosch FX, Kummer JA, Shah KV, Snijders PJ, Peto J, Meijer CJ, Muñoz N: Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol 1999;189:12-19.
  3. Schiffman M, Herrero R, Desalle R, Hildesheim A, Wacholder S, Rodriguez AC, Bratti MC, Sherman ME, Morales J, Guillen D, Alfaro M, Hutchinson M, Wright TC, Solomon D, Chen Z, Schussler J, Castle PE, Burk RD: The carcinogenicity of human papillomavirus types reflects viral evolution. Virology 2005;337:76-84.
  4. de Sanjose S, Quint WG, Alemany L: Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide study. Lancet Oncol 2010;11:1048-1056.
  5. Cuzick J, Clavel C, Petry KU, Meijer CJ, Hoyer H, Ratnam S, Szarewski A, Birembaut P, Kulasingam S, Sasieni P, Iftner T: Overview of the European and North American studies on HPV testing in primary cervical cancer screening. Int J Cancer 2006;119:1095-1101.
  6. de Kok IM, van Rosmalen J, Dillner J, Arbyn M, Sasieni P, Iftner T, van Ballegoojen M: Primary screening for human papillomavirus compared with cytology screening for cervical cancer in European settings: cost effectiveness analysis based on a Dutch microsimulation model. BMJ 2012;344:e670.
  7. Kijkaart DC, Berkhof J, van Kemenade FJ, Coupe VM, Rozendaal, Heideman DA, Verheijen RH, Bulk S, Verweig W, Snijders PJ, Meijer CJ: HPV DNA testing in population-based cervical screening (VUSA-Screen study): results and implications. Br J Cancer 2012;106:975-981.
  8. Farnsworth A: Screening for the prevention of cervical cancer in the era of human papillomavirus vaccination: an Australian perspective. Acta Cytol 2011;55:307-312.
  9. Arbyn M, Anttila A, Jordan J, Schenck U, Ronco G, Segnan N, Wiener H, Herbert A, Daniel J, von Karsa L: European Commission. European Guidelines for Quality Assurance in Cervical Cancer Screening. Second edition - summary document. Ann Oncol 2010;21:448-455.
  10. de Sanjosé S, Diaz M, Castellsagué X, Clifford G, Bruni L, Muñoz N, Bosch FX: Worldwide prevalence and genotype distribution of cervical human papillomavirus DNA in women with normal cytology, a meta-analysis. Lancet Infect Dis 2007;7:453-459.
  11. Garcia-García JA, Pérez-Vallés A, Martorell M, Gómez B, Gómez-Cabrero D, Soler F, Calabuig C: Distribution of human papillomavirus types in women from Valencia, Spain, with abnormal cytology. Acta Cytol 2010;54:159-164.
  12. Klug SJ, Hukelmann M, Hollwitz B, Düzenli N, Schopp B, Petry KU, Iftner T: Prevalence of human papillomavirus types in women screened by cytology in Germany. J Med Virol 2007;79:616-625.
  13. Agarossi A, Ferrazzi E, Parazzini F, Perno CF, Ghisoni L: Prevalence and type distribution of high-risk human papillomavirus infection in women undergoing voluntary cervical cancer screening in Italy. J Med Virol 2009;81:529-535.
  14. Evans MF, Adamson CS, Papillo JL, St John TL, Leiman G, Cooper K: Distribution of human papillomavirus types in ThinPrep Papanicolaou tests classified according to the Bethesda 2001 terminology and correlations with patient age and biopsy outcomes. Cancer 2006;106:1054-1064.
  15. Forslund O, Antonsson A, Edlund K, van den Brule AJ, Hansson BG, Meijer CJ, Ryd W, Rylander E, Strand A, Wadell G, Dillner J, Johansson B: Population-based type-specific prevalence of high-risk human papillomavirus infection in middle-aged Swedish women. J Med Virol 2002;66:535-541.
  16. Schenck U, von Karsa L: Cervical cancer screening in Germany. Eur J Cancer 2000;36:2221-2226.
  17. Stanley M, Lowy DR, Frazer I: Chapter 12, Prophylactic HPV vaccines, underlying mechanisms. Vaccine 2006;24:106-113.
  18. Einstein MH, Baron M, Levin MJ, Chatterjee A, Fox B, Scholar S, Rosen J, Chakhtoura N, Meric D, Dessy FJ, Datta SK, Descamps D, Dubin G, HPV-010 Study Group: Comparative immunogenicity and safety of human papillomavirus (HPV)-16/18 vaccine and HPV-6/11/16/18 vaccine: follow-up from months 12-24 in a phase III randomized study of healthy women aged 18-45 years. Hum Vaccin 2011;7:1343-1358.
  19. Solomon D, Davey D, Kurman R, Moriarty A, O'Connor D, Prey M, Raab S, Sherman M, Wilbur D, Wright T, Young N; Forum Group Members, Bethesda 2001 Workshop: The 2001 Bethesda System, terminology for reporting results of cervical cytology. JAMA 2002;287:2114-2119.
  20. Dijkstra MG, Heideman DA, de Roy SC, Rozendaal L, Berkhof J, van Krimpen K, van Groningen K, Snijders PJ, Meijer CJ, van Kemenade FJ: p16(INK4a) immunostaining as an alternative to histology review for reliable grading of cervical intraepithelial lesions. J Clin Pathol 2010;63:972-977.
  21. Gustinucci D, Passamonti B, Cesarini E, Butera D, Palmieri EA, Bulletti S, Carlani A, Staiano M, D'Amico MR, D'Angelo V, Di Dato E, Martinelli N, Malaspina M, Spita N, Tintori B, Fulciniti F: Role of p16(INK4a) cytology testing as an adjunct to enhance the diagnostic specificity and accuracy in human papillomavirus-positive women within an organized cervical cancer screening program. Acta Cytol 2012;56:506-514.
  22. Hesselink AT, Heideman DA, Berkhof J, Topal F, Pol RP, Meijer CJ, Snijders PJ: Comparison of the clinical performance of PapilloCheck human papillomavirus detection with that of the GP5+/6+-PCR-enzyme immunoassay in population-based cervical screening. J Clin Microbiol 2010;48:797-801.
  23. Schopp B, Holz B, Zago M, Stubenrauch F, Petry KU, Kjaer SK, Iftner T: Evaluation of the performance of the novel PapilloCheck HPV genotyping test by comparison with two other genotyping systems and the HC2 test. J Med Virol 2010;82:605-615.
  24. WHO/ICO Information Centre on HPV and Cervical Cancer (HPV Information Centre): Human papillomavirus and related cancers in Germany. Summary report 2010. www.who.int/hpvcentre (accessed April 12, 2013).
  25. Kovács K, Varnai AD, Bollmann M, Bankfalvi A, Szendy M, Speich N, Schmitt C, Pajor L, Bollmann R: Prevalence and genotype distribution of multiple human papillomavirus infection in the uterine cervix: a 7.5-year longitudinal study in a routine cytology-based screening population in West Germany. J Med Virol 2008;80:1814-1823.
  26. Snijders PJ, van den Brule AJ, Meijer CJ: The clinical relevance of human papillomavirus testing, relationship between analytical and clinical sensitivity. J Pathol 2003;201:1-6.
  27. Klug SJ, Molijn A, Schopp B, Holz B, Iftner A, Quint W,JF Snijders P, Petry KU, Krüger Kjaer S, Munk C, Iftner T: Comparison of the performance of different HPV genotyping methods for detecting genital HPV types. J Med Virol 2008;80:1264-1274.
  28. Bandyopadhyay S, Austin RM, Dabbs D, Zhao C: Adjunctive human papillomavirus DNA testing is a useful option in some clinical settings for disease risk assessment and triage of females with ASC-H Papanicolaou test results. Arch Pathol Lab Med 2008;132:1874-1881.
    External Resources
  29. Davey DD, Greenspan DL, Kurtycz DF, Husain M, Austin RM: Atypical squamous cells, cannot exclude high-grade squamous intraepithelial lesion: review of ancillary testing modalities and implications for follow-up. J Low Genit Tract Dis 2010;14:206-214.
  30. Washiya K, Takamizu R, Kumagai Y, Himeji Y, Kobayashi T, Iwai M, Watanabe J: Worldwide web-based cytological analysis of atypical squamous cells cannot exclude high-grade intraepithelial lesions. Acta Cytol 2012;56:47-54.
  31. Stoler MH, Schiffman M, Atypical Squamous Cells of Undetermined Significance-Low-grade Squamous Intraepithelial Lesion Triage Study (ALTS) Group: Interobserver reproducibility of cervical cytologic and histologic interpretations, realistic estimates from the ASCUS-LSIL Triage Study. JAMA 2001;285:1500-1505.
  32. Smith JS, Melendy A, Rana RK, Pimenta JM: Age-specific prevalence of infection with human papillomavirus in females, a global review. J Adolesc Health 2008;43:5-25.
  33. The Atypical Squamous Cells of Undetermined Significance/Low-Grade Squamous Intraepithelial Lesions Triage Study (ALTS) Group: Human papillomavirus testing for triage of women with cytologic evidence of low-grade squamous intraepithelial lesions, baseline data from a randomized trial. J Natl Cancer Inst 2000;92:397-402.
  34. Iftner T, Eberle S, Iftner A, Holz B, Banik N, Quint W, Straube AN: Prevalence of low-risk and high-risk types of human papillomavirus and other risk factors for HPV infection in Germany within different age groups in women up to 30 years of age, an epidemiological observational study. J Med Virol 2010;82:1928-1939.
  35. Bollmann R, Bankfalvi A, Griefingholt H, Trosic A, Speich N, Schmitt C, Bollmann M: Validity of combined cytology and human papillomavirus (HPV) genotyping with adjuvant DNA-cytometry in routine cervical screening, results from 31,031 women from the Bonn region in West Germany. Oncol Rep 2005;13:915-922.
    External Resources
  36. Clifford GM, Rana RK, Franceschi S, Smith JS, Gough G, Pimenta JM: Human papillomavirus genotype distribution in low-grade cervical lesions, comparison by geographic region and with cervical cancer. Cancer Epidemiol Biomarkers Prev 2005;14:1157-1164.
  37. Smith JS, Lindsay L, Hoots B, Keys J, Franceschi S, Winer R, Clifford GM: Human papillomavirus type distribution in invasive cervical cancer and high-grade cervical lesions, a meta-analysis update. Int J Cancer 2007;121:621-632.
  38. Bosch FX, Burchell AN, Schiffman M, Giuliano AR, de Sanjose S, Bruni L, Tortolero-Luna G, Kjaer SK, Muñoz N: Epidemiology and natural history of human papillomavirus infections and type-specific implications in cervical neoplasia. Vaccine 2008;26(suppl 10):K1-K16.
  39. Ostör AG: Natural history of cervical intraepithelial neoplasia, a critical review. Int J Gynecol Pathol 1993;12:186-192.
  40. Brown DR, Kjaer SK, Sigurdsson K, Iversen OE, Hernandez-Avila M, Wheeler CM, Perez G, Koutsky LA, Tay EH, Garcia P, Ault KA, Garland SM, Leodolter S, Olsson SE, Tang GW, Ferris DG, Paavonen J, Steben M, Bosch FX, Dillner J, Joura EA, Kurman RJ, Majewski S, Muñoz N, Myers ER, Villa LL, Taddeo FJ, Roberts C, Tadesse A, Bryan J, Lupinacci LC, Giacoletti KE, Sings HL, James M, Hesley TM, Barr E: The impact of quadrivalent human papillomavirus (HPV; types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in generally HPV-naive women aged 16-26 years. J Infect Dis 2009;199:926-935.
  41. Philipp W, Honoré N, Sapp M, Cole ST, Streeck RE: Human papillomavirus type 42, new sequences, conserved genome organization. Virology 1992;186:331-334.
ppt logo Download Images (.pptx)


Figures
Thumbnail
Thumbnail

Tables
Thumbnail
Thumbnail